Ulticentre, multinational, phase IIIb clinical experiences. Reprod Biomed Online 2003, 6:432?38. 66. Olivennes FUlticentre, multinational,

Ulticentre, multinational, phase IIIb clinical experiences. Reprod Biomed Online 2003, 6:432?38. 66. Olivennes F
Ulticentre, multinational, phase IIIb clinical experiences. Reprod Biomed Online 2003, 6:432?38. 66. Olivennes F, Fanchin R, Bouchard P, de Ziegler D, Taieb J, Selva J, Frydman R: The single or dual administration of the gonadotropin-releasing GGTI298 supplement hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program. Fertil Steril 1994, 62:468?76. 67. Vlaisavljevic V, Reljic M, Lovrec VG, Kovacic B: Comparable effectiveness using flexible single-dose GnRH antagonist (cetrorelix) and single-dose long GnRH agonist (goserelin) protocol for IVF cycles prospective, randomized study. Reprod Biomed Online PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/27766426 2003, 7:301?08. 68. Dal Prato L, Borini A: Use of antagonists in ovarian stimulation protocols. Reprod Biomed Online 2005, 10:330?38. 69. The Ganirelix dose-finding study group: A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum Reprod 1998, 13:3023?031. 70. Wilcox J, Potter D, Moore M, Ferrande L, Kelly E: Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies. Fertil Steril 2005, 84:108?17. 71. Hsieh YY, Chang CC, Tsai HD: Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization. Taiwan J Obstet Gynecol 2008, 47:66?4. 72. Devroey P, Boostanfar R, Koper NP, Mannaerts BM, Ijzerman-Boon PC, Fauser BC: A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 2009, 24:3063?072.Copperman and Benadiva Reproductive Biology and Endocrinology 2013, 11:20 http://www.rbej.com/content/11/1/Page 12 of73. Nyboe Andersen A, Witjes H, Gordon K, Mannaerts B: Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/ GnRH antagonist protocol with or without oral contraceptive pretreatment. Hum Reprod 2011, 26:3413?423. 74. Depalo R, Jayakrishan K, Garruti G, Totaro I, Panzarino M, Giorgino F, Selvaggi LE: GnRH agonist versus GnRH antagonist in PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/25645579 in vitro fertilization and embryo transfer (IVF/ET). Reprod Biol Endocrinol 2012, 10:26. 75. Ludwig M, Katalinic A, Banz C, Schroder AK, Loning M, Weiss JM, Diedrich K: Tailoring the GnRH antagonist cetrorelix acetate to individual patients’ needs in ovarian stimulation for IVF: results of a prospective, randomized study. Hum Reprod 2002, 17:2842?845. 76. Mochtar MH: The effect of an individualized GnRH antagonist protocol on folliculogenesis in IVF/ICSI. Hum Reprod 2004, 19:1713?718. 77. Felberbaum RE, Diedrich K: Gonadotrophin-releasing hormone antagonists: will they replace the agonists? Reprod Biomed Online 2003, 6:43?3. 78. Obery?J, Study Group on Weight Adjusted Dosing of Ganirelix: No need for dose adjustment of GnRH antagonist based on patient’s body weight in controlled ovarian hyperstimulation with recombinant follicle stimulating hormone. Fertil Steril 2003, 80(Suppl 3):S9. 79. Escudero E, Bosch E, Crespo J, Simon C, Remohi J, Pellicer A: Comparison of two different starting multiple dose g.